TrialAnnals of the rheumatic diseases2015

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Frank Behrens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.